Krogsgaard: We have expanded Victoza’s already strong position
Novo Nordisk’s research chief, Mads Krogsgaard Thomsen, aims to use new strong cardiovascular data on the company’s blockbuster Victoza to win a label expansion in the US and Europe. He is confident the group will consolidate its market position with the fresh data.
BY STEFAN SINGH KAILAY
Novo Nordisk said Friday that its GLP-1 analogue Victoza (liraglutide) – as only the second diabetes treatment ever - had shown a reduction in adverse cardiovascular events.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Rival data could increase pressure on Novo
For abonnenter
Analyst: ”A great day for Novo”
For abonnenter
Here are the most important results from ADA
For abonnenter
